The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases
Open accessAbstract
OBJECTIVE: To evaluate the incremental increase in new onset diabetes from higher potency statins compared with lower potency statins when used for secondary prevention. DESIGN: Eight population based cohort studies and a meta-analysis. SETTING: Six Canadian provinces and two international databases from the UK and US. PARTICIPANTS: 136,966 patients aged ≥ 40 years newly treated with statins between 1 January 1997 and 31 March 2011. METHODS: Within each cohort of patients newly prescribed a statin after hospitalisation for a major cardiovascular event or procedure, we performed as-treated, nested case-control analyses to compare diabetes incidence in users of higher potency statins with incidence in users of lower potency statins. Rate ratios of new diabetes events were estimated using conditional logistic regression on different lengths of exposure to higher potency versus lower potency statins; adjustment for confounding was achieved using high dimensional propensity scores. Meta-analytic methods were used to estimate overall effects across sites. MAIN OUTCOME MEASURES: Hospitalisation for new onset diabetes, or a prescription for insulin or an oral antidiabetic drug. RESULTS: In the first two years of regular statin use, we observed a significant increase in the risk of new onset diabetes with higher potency statins compared with lower potency agents (rate ratio 1.15, 95% confidence interval 1.05 to 1.26). The risk increase seemed to be highest in the first four months of use (rate ratio 1.26, 1.07 to 1.47). CONCLUSIONS: Higher potency statin use is associated with a moderate increase in the risk of new onset diabetes compared with lower potency statins in patients treated for secondary prevention of cardiovascular disease. Clinicians should consider this risk when prescribing higher potency statins in secondary prevention patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-0738 · Cited by 439
Risk of incident diabetes among patients treated with statins: population based study
Carter, A. A., Gomes, T., Camacho, X., Juurlink, D. N., Shah, B. R., & Mamdani, M. M. (2013) · BMJ · doi:10.1136/bmj.f2610 · Cited by 404
Essebag, V., Platt, R. W., Abrahamowicz, M., & Pilote, L. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-5 · Cited by 234
Cited by
Qato, D. M., Wilder, J., Schumm, L. P., Gillet, V., & Alexander, G. C. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.8581 · Cited by 658
Chou, R., Dana, T., Blazina, I., Daeges, M., & Jeanne, T. L. (2016) · JAMA · doi:10.1001/jama.2015.15629 · Cited by 568
Kim, B.-K., Hong, S.-J., Lee, Y.-J., Hong, S. J., Yun, K. H., Hong, B.-K., Heo, J. H., Rha, S.-W., Cho, Y.-H., Lee, S.-J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00916-3 · Cited by 328
Chou, R., Cantor, A., Dana, T., Wagner, J., Ahmed, A. Y., Fu, R., & Ferencik, M. (2022) · JAMA · doi:10.1001/jama.2022.12138 · Cited by 287
Barrios, V., Escobar, C., Cicero, A. F. G., Burke, D., Fasching, P., Banach, M., & Bruckert, E. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2016.10.003 · Cited by 96
Metadata
- Authors
- Dormuth, C. R., Filion, K. B., Paterson, J. M., James, M. T., Teare, G. F., Raymond, C. B., Rahme, E., Tamim, H., Lipscombe, L., & for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2014-05-29
- Volume
- 348
- Issue
- may29 6
- Pages
- g3244-g3244
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W1976531866
- Cited by
- 180
- References
- 11
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.